These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 32540448)
21. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287 [TBL] [Abstract][Full Text] [Related]
22. Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies-A Case-Control Study. Ammendola S; Romeo S; Cattazzo F; Mantovani A; Ieluzzi D; Paon V; Montagnana M; Pecori S; Tomezzoli A; Dalbeni A; Sacerdoti D Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255857 [TBL] [Abstract][Full Text] [Related]
23. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864 [TBL] [Abstract][Full Text] [Related]
25. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. Dammacco F; Sansonno D N Engl J Med; 2013 Sep; 369(11):1035-45. PubMed ID: 24024840 [No Abstract] [Full Text] [Related]
26. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881 [TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy. Mazzaro C; Bomben R; Gragnani L; Visentini M; Pozzato G; Pozzo F; Zucchetto A; Gattei V Semin Hematol; 2022 Oct; 59(4):177-182. PubMed ID: 36805885 [TBL] [Abstract][Full Text] [Related]
28. Extrahepatic manifestations in chronic hepatitis C virus carriers. Rosenthal E; Cacoub P Lupus; 2015 Apr; 24(4-5):469-82. PubMed ID: 25801890 [TBL] [Abstract][Full Text] [Related]
29. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451 [TBL] [Abstract][Full Text] [Related]
31. New insights in cryoglobulinemic vasculitis. Silva F; Pinto C; Barbosa A; Borges T; Dias C; Almeida J J Autoimmun; 2019 Dec; 105():102313. PubMed ID: 31383568 [TBL] [Abstract][Full Text] [Related]
32. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850 [TBL] [Abstract][Full Text] [Related]
33. Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. Shimada M; Nakamura N; Endo T; Yamabe H; Nakamura M; Murakami R; Narita I; Tomita H BMC Nephrol; 2017 Mar; 18(1):109. PubMed ID: 28356063 [TBL] [Abstract][Full Text] [Related]
34. Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis. Conca P; Cafaro G; De Renzo A; Coppola A; Cimino E; Tarantino G Int J Mol Sci; 2015 Jun; 16(6):14075-85. PubMed ID: 26101866 [TBL] [Abstract][Full Text] [Related]
35. [Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents]. Ignatova TM; Chernova OA; Burnevich EZ; Milovanova SIu Klin Med (Mosk); 2014; 92(8):62-4. PubMed ID: 25790700 [TBL] [Abstract][Full Text] [Related]
36. Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit. Zanotti P; Izzo I; Casari S; Cattaneo C; Zaltron S; Spinetti A; Odolini S; Chirico C; Grecchi C; Festa E; Castelli F New Microbiol; 2017 Oct; 40(4):289-290. PubMed ID: 28825444 [TBL] [Abstract][Full Text] [Related]
37. Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. De Blasi T; Aguilar Marucco D; Cariti G; Maiello A; De Rosa FG; Di Perri G Infection; 2008 Jun; 36(3):285-7. PubMed ID: 17962905 [TBL] [Abstract][Full Text] [Related]
38. Cryoglobulinemic vasculitis: a 2023 update. Moretti M; Ferro F; Baldini C; Mosca M; Talarico R Curr Opin Rheumatol; 2024 Jan; 36(1):27-34. PubMed ID: 37916482 [TBL] [Abstract][Full Text] [Related]
39. HCV Treatments and Their Integration Into Rheumatology. Vassilopoulos D; Calabrese LH Curr Rheumatol Rep; 2015 Aug; 17(8):51. PubMed ID: 26113012 [TBL] [Abstract][Full Text] [Related]